Antidote Technologies connects patients and clinical trial sponsors to help accelerate research, explained Tom Krohn, chief development officer, Antidote.
The combined services will provide researchers with access to potential clinical trial participants via Antidote's partner network as well as lab-validated referrals through PWNHealth's physician network and more than 40 lab partners.
“Antidote approached PWN Health to explore options to leverage their direct-to-patient lab service offering in the context of clinical research,” Krohn told us, adding that the companies immediately “found synergy” and moved forward with the partnership.
“Our goal is to better serve the stakeholders in clinical research through advanced pre-screening approaches that incorporate labs,” Krohn explained. “This will help sponsors, patients and research sites together.”
The partnership addresses the increasing inclusion of biomarkers as an eligibility criterion for participation in clinical trials.
“In clinical research, we’re seeing more precision medicine and greater targeting of patient populations, where labs, such as genetic markers and other biomarkers, are key eligibility criteria,” said Krohn.
The partnership is open-ended and focuses on shared value for all stakeholders, he explained: “Precision medicine and research through labs is not one-off need, but a general trend.”
As for next steps, Krohn said some project work is about to launch and additional projects are being explored.
Antidote also recently announced an alliance with phaware, a pulmonary hypertension (PH) advocacy organization. The strategic partnership that will provide patient recruitment services to pharmaceutical companies and contract research organizations (CROs) conducting clinical trials in chronic lung diseases.
